C3G is characterized by C3 deposition in the glomeruli caused by abnormal activation of the alternative complement pathway. There are no approved therapies for C3G. Despite supportive care, C3G remains a progressive form of kidney disease, with novel treatments needed to improve outcomes. Contemporary datasets on the clinical burden of patients with C3G are limited. Using real-world evidence from electronic medical records, this study describes the characteristics of patients diagnosed with C3G in the US.
No takes yet. Share an insight, caveat, or question.
Ndife et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: